@article{3123592,
    title = "Nepafenac ophthalmic suspension 0.3% for the management of ocular pain after photorefractive keratectomy",
    author = "Kontadakis, G.A. and Chronopoulou, K.G. and Tsopouridou, R. and Tabibian, D. and Kymionis, G.D.",
    journal = "Journal of Refractive Surgery",
    year = "2018",
    volume = "34",
    number = "3",
    pages = "171-176",
    publisher = "SLACK Incorporated",
    issn = "1081-597X",
    doi = "10.3928/1081597X-20180123-03",
    keywords = "nepafenac;  benzeneacetamide derivative;  eye drops;  nepafenac;  nonsteroid antiinflammatory agent;  phenylacetic acid derivative, adult;  Article;  astigmatism;  clinical article;  controlled study;  eye pain;  female;  haze;  healing;  human;  male;  myopia;  pain assessment;  photorefractive keratectomy;  postoperative analgesia;  postoperative pain;  priority journal;  prospective study;  randomized controlled trial;  suspension;  treatment outcome;  visual acuity;  comparative study;  excimer laser;  eye pain;  pain measurement;  postoperative pain;  procedures;  therapeutic use;  wound healing;  young adult, Adult;  Anti-Inflammatory Agents, Non-Steroidal;  Astigmatism;  Benzeneacetamides;  Eye Pain;  Female;  Humans;  Lasers, Excimer;  Male;  Myopia;  Ophthalmic Solutions;  Pain Measurement;  Pain, Postoperative;  Phenylacetates;  Photorefractive Keratectomy;  Prospective Studies;  Suspensions;  Visual Acuity;  Wound Healing;  Young Adult",
    abstract = "PURPOSE: To investigate the effect of nepafenac 0.3% in a once daily dosage regarding pain and healing after photorefractive keratectomy (PRK). METHODS: This was a prospective, comparative, contralateral randomized study of 35 patients undergoing PRK for the correction of low to moderate myopia and myopic astigmatism. After randomization, patients received nepafenac 0.3% ophthalmic suspension once daily in one eye (nepafenac 0.3% group) and nepafenac 0.1% ophthalmic suspension three times a day in the other eye (nepafenac 0.1% group) until the second postoperative day. Pain was evaluated every 2 hours on the day of the operation and then once daily using a scale ranging from 0 to 4. Patients were then examined at 2 weeks and 1, 3, 6, and 12 postoperative months. Visual acuity and subepithelial haze were also assessed. RESULTS: No differences were detected between groups in pain scores, subepithelial haze scores, or visual acuity. Refractive predictability was also similar. CONCLUSIONS: Nepafenac 0.3% ophthalmic suspension in a daily regimen after PRK seems to be an effective treatment for pain and ocular discomfort with effects similar to the 0.1% suspension. © 2018 Slack Incorporated. All rights reserved."
}